Developmental Endothelial Locus-1, Platelet Count, and Soluble P-selectin in Overweight and Obese Subjects
NCT ID: NCT05864079
Last Updated: 2024-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
66 participants
OBSERVATIONAL
2023-06-01
2024-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is there a difference in serum DEl-1 levels in overweight and obese subjects compared to normal subjects?
* Are there any relations between serum DEL-1 levels, sP-sel, and platelet count in overweight and obese subjects ?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
NCT07349277
Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity
NCT02331199
Determination of Maternal and Neonatal Apelinemia in Obese Women During Pregnancy
NCT02796456
Point-of-care Ultrasound Abnormalities in Early Onset Preeclampsia
NCT05662995
Mother Infant Nutrition Study
NCT04132310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
22 healthy age-matched normal-weight male subjects (BMI is from 18.5 to \< 25)
Platelet count
Platelet count in study groups
Developmental endothelial locus-1 (DEL-1)
Serum DEL-1 in study groups
soluble P-selectin (sP-sel)
Serum sP-sel in study groups
Overweight
22 healthy overweight male subjects (BMI is from 25 to \< 30). Patients with cardiovascular diseases, any malignancy, hepatic or renal failure, diabetic, hyperthyroid patients, patients with a previous history of thromboembolic diseases, or with a history of major surgery within 60 days will be excluded.
Platelet count
Platelet count in study groups
Developmental endothelial locus-1 (DEL-1)
Serum DEL-1 in study groups
soluble P-selectin (sP-sel)
Serum sP-sel in study groups
Obesity
22 healthy obese male subjects (BMI is ≥ 30). Patients with cardiovascular diseases, any malignancy, hepatic or renal failure, diabetic, hyperthyroid patients, patients with a previous history of thromboembolic diseases, or with a history of major surgery within 60 days will be excluded.
Platelet count
Platelet count in study groups
Developmental endothelial locus-1 (DEL-1)
Serum DEL-1 in study groups
soluble P-selectin (sP-sel)
Serum sP-sel in study groups
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Platelet count
Platelet count in study groups
Developmental endothelial locus-1 (DEL-1)
Serum DEL-1 in study groups
soluble P-selectin (sP-sel)
Serum sP-sel in study groups
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age (18-65) years.
* Healthy overweight and subjects.
Exclusion Criteria
* Diabetic patients.
* Previous history of thrombo-embolic diseases.
* Patients with hyperthyroidism.
* Patients with any type of malignancy.
* Underlying hepatic or renal failure.
* Major surgery within 60 days.
18 Years
65 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aswan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asmaa Abdel-mageed Muhammed
Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Asmaa Abdelmageed Muhammed, lecturer
Role: PRINCIPAL_INVESTIGATOR
Aswan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aswan University Hospital
Aswān, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hajishengallis G, Chavakis T. DEL-1-Regulated Immune Plasticity and Inflammatory Disorders. Trends Mol Med. 2019 May;25(5):444-459. doi: 10.1016/j.molmed.2019.02.010. Epub 2019 Mar 15.
Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. 2021 Mar;106(3):306-319. doi: 10.1111/ejh.13560. Epub 2020 Dec 13.
Barale C, Russo I. Influence of Cardiometabolic Risk Factors on Platelet Function. Int J Mol Sci. 2020 Jan 17;21(2):623. doi: 10.3390/ijms21020623.
Kwon CH, Sun JL, Kim MJ, Abd El-Aty AM, Jeong JH, Jung TW. Clinically confirmed DEL-1 as a myokine attenuates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes via AMPK/HO-1- pathway. Adipocyte. 2020 Dec;9(1):576-586. doi: 10.1080/21623945.2020.1823140.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DEL-1 and sP-sel in obesity
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.